A 63% objective response rate from a Phase 1 monotherapy arm is an unusual number to anchor a strategic pivot on, but that is what BridgeBio Oncology Therapeutics is doing. The company disclosed new clinical data for BBO-8520 on September 8, 2026, via an 8-K filing, and simultaneously named combination therapy in second-line or later KRASG12C-mutant NSCLC as the program’s primary path forward, with two additional combinations, BBO-11818 and BBO-10203, targeted at broader KRAS-mutant cancers.
BBO-8520 is being evaluated in the ONKORAS-101 study (NCT06343402), an ongoing Phase 1a/1b open-label trial. The monotherapy signal comes from KRASG12C inhibitor-naïve patients in the second-line setting, a population that already has approved options: sotorasib received FDA accelerated approval for this indication in 2021, and adagrasib followed. The clinical question BBOT is betting on is whether BBO-8520 combinations can move response rates or durability beyond what those agents deliver. The filing does not specify combination efficacy figures yet, so the pivot to combinations is prospective, not already proven in the data disclosed today.
The FDA cleared BBO-8520’s IND in January 2024 and granted it Fast Track designation for adult patients in this setting, which gives the program access to more frequent FDA interactions and rolling review eligibility, though it does not accelerate efficacy requirements. Fast Track status matters most if combination data, when they arrive, are compelling enough to support an accelerated approval application before a full Phase 3 is complete.
The disclosure bundles three programs into one announcement, which makes it harder to assess where resources are actually concentrating. What will clarify the strategy is whether ONKORAS-101 expansion cohorts testing BBO-8520 combinations report response data before the end of 2026, and whether those numbers hold up against the durability bar that has tripped up earlier KRASG12C inhibitors in heavily pretreated patients.
Source link: https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/d97546d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
